TABLE 1.
BASELINE CHARACTERISTICS OF THE 1,204 SUBJECTS INCLUDED IN THE ANALYSIS
| Surgical Cohort | Medical Cohort | ||
|---|---|---|---|
| (n = 601) | (n = 603) | P Value | |
| Age, yr | 66.8 ± 6.4 | 66.9 ± 5.9 | P = 0.69 |
| Male sex, n (%) | 351 (58) | 388 (64) | P = 0.04 |
| FEV1, L/s | 0.76 ± 0.24 | 0.78 ± 0.24 | P = 0.21 |
| FEV1,% predicted | 27 ± 7 | 27 ± 7 | P = 0.8 |
| Charlson score* | 0.75 ± 1.25 | 0.73 ± 1.22 | P = 0.72 |
| Oral steroids† | 35% | 28% | P = 0.01 |
| Inhaled steroids | 68% | 71% | P = 0.21 |
| Long-acting sympathomimetics‡ | 45% | 45% | P = 0.91 |
| Resting oxygen supplementation | 50% | 51% | P = 0.69 |
| Nocturnal oxygen supplementation | 65% | 66% | P = 0.9 |
| Individuals having an exacerbation | 156 | 154 | |
| Exacerbation rate, per person-year | 0.36 | 0.34 | P = 0.58 |
| Range, per person | 0–6 | 0–5 |
*
n = 600 for the surgical cohort and n = 602 for the medical cohort.
†
Subjects were required to be on a stable dose of ⩽20mg of prednisone or its equivalent per the original screening criteria.
‡
β-Agonists such as salmeterol.